SPP2

Summary

SPP2 (secreted phosphoprotein 2, HGNC:11256) is a protein-coding gene on chromosome 2q37.1, encoding Secreted phosphoprotein 24 (Q13103). Could coordinate an aspect of bone turnover.

This gene encodes a secreted phosphoprotein that is a member of the cystatin superfamily.

Source: NCBI Gene 6694 — RefSeq curated summary.

At a glance

• Gene–disease (curated): retinitis pigmentosa (Limited, GenCC)
• Clinical variants (ClinVar): 215 total — 1 likely-pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_006944

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11256
Approved symbol	SPP2
Name	secreted phosphoprotein 2
Location	2q37.1
Locus type	gene with protein product
Status	Approved
Aliases	SPP24
Ensembl gene	ENSG00000072080
Ensembl biotype	protein_coding
OMIM	602637
Entrez	6694

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 17 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000168148, ENST00000373368, ENST00000425558, ENST00000492481, ENST00000874733, ENST00000874734, ENST00000874735, ENST00000874736, ENST00000874737, ENST00000874738, ENST00000874739, ENST00000874740, ENST00000874741, ENST00000874742, ENST00000874743, ENST00000874744, ENST00000874745, ENST00000874746

RefSeq mRNA: 1 — MANE Select: NM_006944 NM_006944

CCDS: CCDS2511

Canonical transcript exons

ENST00000168148 — 8 exons

Exon	Start	End
ENSE00000398689	234050702	234050871
ENSE00000786992	234060369	234060479
ENSE00000786993	234066533	234066587
ENSE00000786994	234067224	234067274
ENSE00000839699	234069928	234070023
ENSE00001417090	234076845	234077134
ENSE00003601942	234050971	234051095
ENSE00003635167	234058836	234058958

Expression profiles

Bgee: expression breadth broad, 75 present calls, max score 96.85.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.4820 / max 217.3046, expressed in 11 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
26127	0.2798	10
26126	0.1176	8
26125	0.0847	8

Top tissues by expression

254 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	96.85	gold quality
liver	UBERON:0002107	95.91	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.34	gold quality
triceps brachii	UBERON:0001509	68.52	gold quality
gluteal muscle	UBERON:0002000	68.40	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	66.19	gold quality
endothelial cell	CL:0000115	62.60	gold quality
orbitofrontal cortex	UBERON:0004167	62.44	gold quality
gingival epithelium	UBERON:0001949	61.90	gold quality
diaphragm	UBERON:0001103	61.83	gold quality
secondary oocyte	CL:0000655	61.06	gold quality
upper arm skin	UBERON:0004263	61.04	gold quality
periodontal ligament	UBERON:0008266	60.55	gold quality
CA1 field of hippocampus	UBERON:0003881	59.84	gold quality
quadriceps femoris	UBERON:0001377	59.74	gold quality
vastus lateralis	UBERON:0001379	59.42	gold quality
tongue squamous epithelium	UBERON:0006919	58.87	gold quality
oocyte	CL:0000023	58.43	gold quality
gingiva	UBERON:0001828	58.31	gold quality
deltoid	UBERON:0001476	58.18	gold quality
ileal mucosa	UBERON:0000331	58.07	silver quality
mucosa of urinary bladder	UBERON:0001259	57.94	gold quality
decidua	UBERON:0002450	57.03	gold quality
epithelium of esophagus	UBERON:0001976	56.74	gold quality
tibialis anterior	UBERON:0001385	56.54	silver quality
Brodmann (1909) area 23	UBERON:0013554	56.12	gold quality
squamous epithelium	UBERON:0006914	55.88	gold quality
middle temporal gyrus	UBERON:0002771	55.14	gold quality
germinal epithelium of ovary	UBERON:0001304	54.90	gold quality
epithelium of nasopharynx	UBERON:0001951	54.76	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.41

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

12 targeting SPP2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-6715A-3P	99.83	68.05	1473
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-6844	99.82	70.69	2423
HSA-MIR-646	99.68	67.84	1645
HSA-MIR-10399-5P	99.17	69.87	2610
HSA-MIR-6504-3P	99.17	69.31	2891
HSA-MIR-4738-3P	98.98	67.98	1846
HSA-MIR-2278	97.30	66.19	1130
HSA-MIR-383-5P	96.86	67.55	820
HSA-MIR-132-5P	96.61	65.79	115

Literature-anchored findings (GeneRIF, showing 11)

• Results describe the localization of the human secreted phosphoprotein 24 gene, its structure and the start of transcription in liver. (PMID:15062857)
• spp24 contains at least 2 single nucleotide polymorphisms. Given its mechanism of action and sequence variability, SPP24 may be an interesting candidate for future studies of the genetic regulation of bone mass. (PMID:19375587)
• Spp24, or proteolytic products of Spp24, bind cytokines of the TGF-beta superfamily and also activate intracellular signaling pathways [review] (PMID:25339413)
• Report describes a C-terminal fragment within SPP24 that is distinct from the cystatin domain and which independently binds to BMP-2 and TGF-beta. This fragment inhibited BMP-2 activity in an ectopic bone forming assay. (PMID:25418420)
• Spp24 truncation products have effects on osteoblastic differentiation mediated by kinase pathways that are independent of exogenous BMP/TGF-beta cytokines. (PMID:25501958)
• the two mutations of SPP2 have dominant negative effects and cellular accumulation of Spp-24 might be particularly toxic to photoreceptors and/or retinal pigment epithelium. SPP2 has a new role in retinal degeneration. (PMID:26459573)
• Spp24 can inhibit the growth of prostate cancer and its bone metastasis induced by BMP2; spp24 may have great potential to be a therapeutic agent in clinical situations (PMID:27793899)
• SPP2 expression was decreased in colorectal cancer, leukemia, liver cancer and pancreatic cancer. (PMID:31849319)
• Secreted Phosphoprotein 24 is a Biomarker of Mineral Metabolism. (PMID:33481052)
• Secreted phosphoprotein 24 kD (Spp24) inhibits the growth of human osteosarcoma through the BMP-2/Smad signaling pathway. (PMID:36883270)
• SPP2 plays a role in the tumorigenesis of hepatocellular carcinoma: A bioinformatic based analysis. (PMID:38448371)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	spp2	ENSDARG00000095590
mus_musculus	Spp2	ENSMUSG00000026295
rattus_norvegicus	Spp2	ENSRNOG00000053244

Protein

Protein identifiers

Secreted phosphoprotein 24 — Q13103 (reviewed: Q13103)

Alternative names: Secreted phosphoprotein 2

All UniProt accessions (2): Q13103, C9J6K0

UniProt curated annotations — full annotation on UniProt →

Function. Could coordinate an aspect of bone turnover.

Subcellular location. Secreted.

Tissue specificity. Detected in liver and plasma.

Post-translational modifications. Phosphorylation sites are present in the extracellular medium.

Similarity. Belongs to the SPP2 family.

RefSeq proteins (1): NP_008875* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR010892	Spp-24	Family
IPR046350	Cystatin_sf	Homologous_superfamily

Pfam: PF07448

UniProt features (12 total): modified residue 6, disulfide bond 2, signal peptide 1, chain 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q13103-F1	69.68	0.36

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 96, 145, 146, 170, 173, 182

Disulfide bonds (2): 92–103, 116–134

Function

Pathways and Gene Ontology

Reactome pathways

8 pathways

ID	Pathway
R-HSA-114608	Platelet degranulation
R-HSA-381426	Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
R-HSA-8957275	Post-translational protein phosphorylation
R-HSA-109582	Hemostasis
R-HSA-392499	Metabolism of proteins
R-HSA-597592	Post-translational protein modification
R-HSA-76002	Platelet activation, signaling and aggregation
R-HSA-76005	Response to elevated platelet cytosolic Ca2+

MSigDB gene sets: 87 (showing top): GOBP_SKELETAL_SYSTEM_DEVELOPMENT, GOCC_SECRETORY_GRANULE, REACTOME_PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION, GNF2_HPN, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_DN, GNF2_LCAT, HSIAO_LIVER_SPECIFIC_GENES, GNF2_HPX, MODULE_88, TGGNNNNNNKCCAR_UNKNOWN, CDPCR3HD_01, MODULE_95, TGGAAA_NFAT_Q4_01, GOCC_SECRETORY_VESICLE

GO Biological Process (3): skeletal system development (GO:0001501), bone remodeling (GO:0046849), protein-containing complex assembly (GO:0065003)

GO Molecular Function (1): endopeptidase inhibitor activity (GO:0004866)

GO Cellular Component (4): extracellular region (GO:0005576), endoplasmic reticulum lumen (GO:0005788), platelet dense granule lumen (GO:0031089), protein-containing complex (GO:0032991)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Metabolism of proteins	2
Response to elevated platelet cytosolic Ca2+	1
Post-translational protein modification	1
Hemostasis	1
Platelet activation, signaling and aggregation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
system development	1
tissue remodeling	1
cellular component assembly	1
protein-containing complex organization	1
endopeptidase activity	1
peptidase inhibitor activity	1
endopeptidase regulator activity	1
cellular anatomical structure	1
endoplasmic reticulum	1
intracellular organelle lumen	1
secretory granule lumen	1
platelet dense granule	1
cellular_component	1

Protein interactions and networks

STRING

808 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SPP2	AHSG	P02765	899
SPP2	CUX1	P39880	772
SPP2	MGP	P08493	730
SPP2	CDC37L1	Q7L3B6	552
SPP2	TAPT1	Q6NXT6	496
SPP2	CP	P00450	491
SPP2	SERPINC1	P01008	475
SPP2	ALB	P02768	463
SPP2	BMP2	P12643	446
SPP2	BMP7	P18075	443
SPP2	CMPK1	P30085	440
SPP2	KRT2	P35908	440
SPP2	CEBPA	P49715	440
SPP2	SERPINA3	P01011	431
SPP2	GALNT1	Q10472	427

IntAct

2 interactions, top by confidence:

A	B	Type	Score
SPP2	FAM20C	psi-mi:“MI:0217”(phosphorylation reaction)	0.440

BioGRID (1): SPP2 (Positive Genetic)

ESM2 similar proteins: B6D434, B6S2X0, B6S2X2, O08692, O18752, O18753, O18755, O70183, O97759, P01042, P14082, P21237, P23363, P23470, P23560, P54228, Q05909, Q0EAB7, Q13103, Q1KLX9, Q1KLY0, Q1KLY2, Q1KLY3, Q27967, Q2F7Z7, Q2IAL7, Q3SAT7, Q3T0Q2, Q49M28, Q4L0Y3, Q4R8C8, Q5IS78, Q5R800, Q5W186, Q62740, Q6LCI5, Q70I47, Q70TH4, Q710A0, Q710A1

Diamond homologs: Q13103, Q27967, Q62740, Q70I47, Q70TH4, Q710A0, Q710A1, Q711S8, Q8K1I3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

215 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	119
Likely benign	76
Benign	7

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
3027529	NM_006944.3(SPP2):c.49_52dup (p.Phe18fs)	Likely pathogenic

SpliceAI

1106 predictions. Top by Δscore:

Variant	Effect	Δscore
2:234066497:A:AG	acceptor_gain	1.0000
2:234066497:AT:A	acceptor_gain	1.0000
2:234066497:ATGT:A	acceptor_gain	1.0000
2:234066498:T:G	acceptor_gain	1.0000
2:234066498:T:TA	acceptor_gain	1.0000
2:234066503:T:A	acceptor_gain	1.0000
2:234050868:TCAG:T	donor_loss	0.9900
2:234050869:CAG:C	donor_loss	0.9900
2:234050870:AG:A	donor_loss	0.9900
2:234050871:GGTAA:G	donor_loss	0.9900
2:234050872:G:A	donor_loss	0.9900
2:234051094:GA:G	donor_gain	0.9900
2:234060367:A:AG	acceptor_gain	0.9900
2:234060368:G:GA	acceptor_gain	0.9900
2:234066500:T:TA	acceptor_gain	0.9900
2:234069922:CTTTA:C	acceptor_loss	0.9900
2:234069923:TTTA:T	acceptor_loss	0.9900
2:234069924:TTAG:T	acceptor_loss	0.9900
2:234069925:TAG:T	acceptor_loss	0.9900
2:234069926:A:C	acceptor_loss	0.9900
2:234069926:AG:A	acceptor_gain	0.9900
2:234069927:G:T	acceptor_loss	0.9900
2:234069927:GG:G	acceptor_gain	0.9900
2:234070019:TTGAG:T	donor_loss	0.9900
2:234070020:TGAGG:T	donor_loss	0.9900
2:234070021:GAGG:G	donor_loss	0.9900
2:234070022:AG:A	donor_loss	0.9900
2:234070023:GG:G	donor_loss	0.9900
2:234070024:G:T	donor_loss	0.9900
2:234070025:T:G	donor_loss	0.9900

AlphaMissense

1403 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:234060387:A:C	S118R	0.994
2:234060389:C:A	S118R	0.994
2:234060389:C:G	S118R	0.994
2:234058879:T:C	F85S	0.991
2:234060381:T:A	C116S	0.990
2:234060382:G:C	C116S	0.990
2:234058879:T:G	F85C	0.987
2:234060381:T:C	C116R	0.986
2:234051041:T:A	N52K	0.985
2:234051041:T:G	N52K	0.985
2:234060382:G:A	C116Y	0.985
2:234060435:T:A	C134S	0.985
2:234060436:G:C	C134S	0.985
2:234051025:C:T	S47F	0.982
2:234060383:C:G	C116W	0.982
2:234051025:C:A	S47Y	0.981
2:234058878:T:C	F85L	0.981
2:234058880:C:A	F85L	0.981
2:234058880:C:G	F85L	0.981
2:234058894:C:T	T90I	0.981
2:234058899:T:A	C92S	0.981
2:234058900:G:C	C92S	0.981
2:234058939:T:G	F105C	0.981
2:234058899:T:C	C92R	0.978
2:234058932:T:C	C103R	0.978
2:234058932:T:A	C103S	0.977
2:234058933:G:C	C103S	0.977
2:234060435:T:C	C134R	0.975
2:234058900:G:A	C92Y	0.973
2:234058901:C:G	C92W	0.971

dbSNP variants (sampled 300 via entrez): RS1000107810 (2:234049773 A>G), RS1000136411 (2:234067437 C>T), RS1000696420 (2:234076931 T>G), RS1000833950 (2:234060028 C>T), RS1000846133 (2:234050344 G>C), RS1000887782 (2:234054224 A>G), RS1000919394 (2:234071172 T>G), RS1001075211 (2:234067706 G>A), RS1001100548 (2:234061201 AATTAT>A), RS1001148226 (2:234065916 T>C), RS1001172611 (2:234056200 T>A,C), RS1001292555 (2:234059739 C>T), RS1001324788 (2:234056490 T>G), RS1001359289 (2:234067829 C>G,T), RS1001494829 (2:234061965 T>C)

Disease associations

OMIM: gene MIM:602637 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
retinitis pigmentosa	Limited	Autosomal dominant

Mondo (2): inherited retinal dystrophy (MONDO:0019118), retinitis pigmentosa (MONDO:0019200)

Orphanet (1): OBSOLETE: Inherited retinal disorder (Orphanet:71862)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000556	Retinal dystrophy

GWAS associations

0 associations (top):

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D058499	Retinal Dystrophies	C11.768.585.658
D012174	Retinitis Pigmentosa	C11.270.684; C11.768.585.658.500; C16.320.290.684

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

40 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects methylation, decreases expression	2
Benzo(a)pyrene	decreases expression, increases methylation	2
Aflatoxin B1	affects expression, decreases expression	2
2,4,6-tribromophenol	decreases expression	1
methyleugenol	decreases expression	1
uranyl acetate	affects expression	1
propionaldehyde	decreases expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
bisphenol A	decreases expression	1
diisononyl phthalate	decreases expression, affects cotreatment	1
lead nitrate	affects cotreatment, decreases expression	1
tetrabromobisphenol A	decreases expression	1
perfluorooctanoic acid	decreases expression	1
butylbenzyl phthalate	affects cotreatment, decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
perfluoro-n-nonanoic acid	decreases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
Rosiglitazone	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Troglitazone	decreases expression	1
Chenodeoxycholic Acid	affects cotreatment, decreases expression	1
Copper	affects cotreatment, decreases expression	1
Deoxycholic Acid	affects cotreatment, decreases expression	1
Diethylhexyl Phthalate	affects cotreatment, decreases expression	1
Estradiol	decreases expression	1
Glycochenodeoxycholic Acid	affects cotreatment, decreases expression	1
Glycocholic Acid	affects cotreatment, decreases expression	1
Glycodeoxycholic Acid	decreases expression, affects cotreatment	1

Clinical trials (associated diseases)

259 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00717080	PHASE4	COMPLETED	The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction
NCT00000114	PHASE3	COMPLETED	Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa
NCT00000116	PHASE3	COMPLETED	Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A
NCT00346333	PHASE3	COMPLETED	Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A
NCT01786395	PHASE3	TERMINATED	Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa
NCT04224207	PHASE3	COMPLETED	Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton’s Jelly Derived Mesenchymal Stem Cells
NCT04636853	PHASE3	COMPLETED	CB-PRP in Retinitis Pigmentosa and Dry Age-related Macular Degeneration
NCT05537220	PHASE3	ACTIVE_NOT_RECRUITING	Oral N-acetylcysteine for Retinitis Pigmentosa
NCT05800301	PHASE3	COMPLETED	Management of Retinitis Pigmentosa Via Combination of Wharton’s Jelly-derived Mesenchymal Stem Cells and Magnovision
NCT05926583	PHASE3	ACTIVE_NOT_RECRUITING	A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa
NCT06388200	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
NCT07082855	PHASE3	NOT_YET_RECRUITING	A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa
NCT07290530	PHASE3	NOT_YET_RECRUITING	24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
NCT00100230	PHASE2	COMPLETED	DHA and X-Linked Retinitis Pigmentosa
NCT00447980	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
NCT00447993	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
NCT01233609	PHASE2	COMPLETED	Trial of Oral Valproic Acid for Retinitis Pigmentosa
NCT01399515	PHASE2	COMPLETED	Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa
NCT01530659	PHASE2	COMPLETED	Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
NCT01560715	PHASE2	COMPLETED	Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa
NCT02609165	PHASE2	COMPLETED	Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema
NCT02661711	PHASE2	COMPLETED	Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study
NCT02804360	PHASE2	UNKNOWN	Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective Study
NCT02837640	PHASE2	UNKNOWN	Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa
NCT03073733	PHASE2	COMPLETED	Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa
NCT04068207	PHASE2	COMPLETED	Minocycline Treatment in Retinitis Pigmentosa
NCT04356716	PHASE2	COMPLETED	Sildenafil for Treatment of Choroidal Ischemia
NCT04604899	PHASE2	COMPLETED	Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa
NCT04763369	PHASE2	UNKNOWN	Investigation of Therapeutic Efficacy and Safety of UMSCs for the Management of Retinitis Pigmentosa (RP)
NCT04864496	PHASE2	UNKNOWN	Effects of Treatment With N- Acetylcysteine on Visual Outcomes in Patients With Retinitis Pigmentosa
NCT04945772	PHASE2	COMPLETED	Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
NCT05085964	PHASE2	TERMINATED	An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
NCT05392179	PHASE2	COMPLETED	A Study in Subjects With Retinitis Pigmentosa
NCT06627179	PHASE2	RECRUITING	Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT06628947	PHASE2	RECRUITING	A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
NCT06912633	PHASE2	RECRUITING	Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
NCT03763227	PHASE2	COMPLETED	Intravitreal Ranibizumab (Lucentis®) in the Treatment of Non-leaking Macular Cysts in Retinal Dystrophy
NCT00063765	PHASE1	COMPLETED	Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye
NCT00065455	PHASE1	COMPLETED	Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa
NCT00458575	PHASE1	TERMINATED	A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa